Clinical trial for Heart Failure; With Decompensation
Official title Biomarker Guided Discharge of Heart Failure Patients
ClinicalTrials.gov ID: NCT03103932
What this study is testing
- What it's testing
- The study wants to see if using NT‑proBNP blood test results to guide discharge decisions improves outcomes compared with usual care.
- Who it's for
- Adults who are in the hospital because of acute decompensated heart failure.
- What's involved
- Participants are randomly assigned (2:1) to a biomarker‑guided discharge plan or standard care. Blood samples for NT‑proBNP are taken within 24 hours of admission, again after 2‑3 days, before discharge, and 30 days after leaving the hospital. Follow‑up includes a phone call at 3 months and a clinic visit at 6 months.
- Time commitment
- Hospital stay with the scheduled blood tests, a phone call at 3 months, and one in‑person visit at 6 months.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients admitted to hospital with a primary diagnosis of acute decompensated heart failure, compatible with the modified Framingham criteria
You likely can't join if
- Patient unable to provide blood samples or cannot participate in follow-up
- Patient with end stage organ failure
- Kidney: creatinine \>350 μmol/L or Estimated GFR ≤15 ml/min
- Liver dysfunction: liver function test \>2.5 times normal
- Lungs: pulmonary FEV1\<50% predicted
- Patient requiring intubation
See the full eligibility criteria
- Patients admitted to hospital with a primary diagnosis of acute decompensated heart failure, compatible with the modified Framingham criteria
- Patient unable to provide blood samples or cannot participate in follow-up
- Patient with end stage organ failure
- Kidney: creatinine \>350 μmol/L or Estimated GFR ≤15 ml/min
- Liver dysfunction: liver function test \>2.5 times normal
- Lungs: pulmonary FEV1\<50% predicted
- Patient requiring intubation
- Patient with an admission NTproBNP measurement of \>30,000 pg/ml
- Patient listed for heart transplant, or admitted specifically for transplant workup
- Patient in cardiogenic shock
- Patient with life expectancy of less than 6 months, or has major co-morbidities such as new stroke, cancer, pneumonia, or other serious life threatening illness
- Patient with conditions that will make it difficult to discharge from hospital such as a fall or waiting for a long term care bed
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the trial, or may bias the result of the trial, or the patient's...
- Patient who has participated in another research trial involving an investigational product in the past 30 days
The study team makes the final eligibility decision.
Where it is enrolling
- Ottawa, Ontario, Canada
Compensation & support
A stipend or payment for your time may be offered.
No amount is published here because ClinicalTrials.gov has no reliable field for payment or travel support. Ask the study team what's actually covered (payment for your time, travel, parking, or other study costs), and never join a trial for the compensation alone.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team, so confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Ottawa, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.